Author: Dino Mustafić

January 24, 2025 Off

Medix Biochemica buys German CANDOR Bioscience

By Dino Mustafić

Medix Biochemica, a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, announced the acquisition of CANDOR Bioscience GmbH, a Germany-based developer and manufacturer of premium immunoassay solutions.

January 17, 2025 Off

RTW Biotech Opportunities Ltd with additional investment in Umoja Biopharma

By Dino Mustafić

RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company has made an additional investment in the Series C financing round of Umoja Biopharma (“Umoja”), a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in oncology and autoimmune treatments.

January 13, 2025 Off

Cube Biotech and IBA Lifesciences in acquisition deal

By Dino Mustafić

 Cube Biotech and IBA Lifesciences join forces to advance research and production capabilities for the life science industry by leveraging its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.

January 13, 2025 Off

Moderna achieves $3B in product sales in 2024

By Dino Mustafić

Moderna announced Monday business updates and progress across its pipeline of mRNA medicines, entering 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need, as it achieved $3-3.1B in product sales.